YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly developed by YD Bio and EG BioMed, into JoiiUp’s JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions.
Covered in this story
Call it yourself
No calls on $DNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ginkgo Bioworks Holdings Inc Class →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.